Skip to main content
Equibles
KRSA logo

KRSA · Korsana Biosciences, Inc. · Metrics

Track KRSA — free

Use KRSA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KRSA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$30.00 -0.22 (-0.73%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 4, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern.”
View the 10-Q filed Aug 4, 2026
Market Cap
$20.21M
Shares
668,764
Volume · Oct 30 3732 Avg daily vol (37 sessions) 114.65K

KRSA metrics

51 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$30.22
Market cap
$20.21M

Price action

20 metrics
Price change (1W)
-9.6%
Price change (30D)
-5.6%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
48.3
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
114,647
Relative volume
1.2
Average dollar volume
$3.72M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
668,764

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
10.6×
reciprocal yield 9.4%
P / book
4.0
reciprocal yield 25.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-33.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-04-01

Profitability

9 metrics
Gross margin
—
Operating margin
-359.2%
Trailing 12 months
Net margin
-353.0%
Gross profit (TTM)
—
Operating profit (TTM)
−$6.82M
Net income (TTM)
−$6.71M
Trailing 12 months
Diluted EPS (TTM)
$-11.27
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$16.64

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.90M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+38.4%
Year over year · more shares
Revenue CAGR (3Y)
+91.1%
Revenue CAGR (5Y)
-2.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-131.8%
Return on assets
-96.8%
Debt / equity
—
Current ratio
0.8
EBITDA (TTM)
−$12.95M
Free cash flow (TTM)
—
Quick ratio
0.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.39M
Total assets
$6.93M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$4.45M
Capital expenditures (TTM)
—
R&D (TTM)
$1.60M
SG&A (TTM)
—
Stock compensation (TTM)
$322,000
R&D / revenue
84.1%
Stock compensation / revenue
16.9%

Ownership (13F)

9 metrics
13F filers
21
13F filer change QoQ
+4
Institutional ownership
70.5%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
57.4%
Private-fund adviser ownership
56.8%
Active holders' share change QoQ
+8,361.1%
Holder tenure
6.5
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
1.8%

Short interest

3 metrics
Short interest
3.6%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
58 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1755237 CUSIP 23255M303 13F (30d) 2 filings 2 filers Visit website Investor relations